期刊论文

Mechanism of Shenkangwan and etanercept in protecting kidney of type 2 diabetic rats

中文

广东医学

1001-9448

2019

40

16

2283-2288

10.13820/j.cnki.gdyx.20191354

江门市科学技术局计划项目（编号:2014020）；

本校为第一机构

目的 观察肾康丸及依那西普对2型糖尿病(T2DM)大鼠肾组织肿瘤坏死因子相关凋亡诱导配体(TRAIL)系统表达的影响,探讨两种药物对肾脏保护的作用机制.方法 建立T2DM大鼠模型为模型组(D组),成模后将大鼠随机分为3组:模型对照组(DM组)、肾康丸组(DS组)、依那西普组(DE组);另设正常对照组(C组).分组干预,全自动生化仪检测尿素氮(BUN)、血肌酐(Scr)及空腹血糖(FBG);ELISA法检测尿微量白蛋白(Uα1-MG)、24 h尿微量白蛋白(24hUm-Alb);Q-RT-PCR法检测治疗后TNF-α、TRAIL、DR4、DcR2在各大鼠肾组织的表达,HE染色法观察大鼠肾组织病理变化.结果 DM组BUN、Scr及FBG上升,与DM组相比,DS组与DE组BUN、Scr、及FB...

Objective To investigate the effects of Shenkangan and etanercept on the expression of tumor necrosis factor-related apoptosis-inducing ligand system(TRAIL)in kidney of type 2 diabetic rats.Methods The rat models of type 2 diabetes were randomly divided into diabetic model group(DM),Shenkangwan treatment group(DS)and etanercept treatment group(DE);while the rat fed with normal chow were selected as the control group(C).After treatment,the BUN,SCr and FBG were assessed by automatic biochemical analyzer.The levels of urineα1-MG(Uα1-MG)and 24 ho...